FDA
-
-
-
-
-
-
-
The $225B Precision Sprint: How Big Pharma is Beating the $170B Patent Cliff
-
-
-
-
-
-
-
Coherus Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update
-
-
-
-
-
-
-
Coherus BioSciences (CHRS) Presents Prelim Results from Phase I Dose Escalation Study of CHS-114
-
-
-
-
-
-
-
Coherus BioSciences Announces CFO Transition Plans
-
-
-
-
-
-
-
Coherus Announces Three Presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
-
-
-
-
-
-
-
Coherus and Junshi Biosciences Announce Toripalimab Studies to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
-
-
-
-
-
-
-
Coherus Granted Permanent, Product-Specific Q-Code for CIMERLIĀ® (ranibizumab-eqrn) from the Centers for Medicare and Medicaid Services
-
329,723 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

